Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a meta-analysis.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
08 2022
Historique:
revised: 24 03 2022
received: 28 12 2021
accepted: 08 05 2022
pubmed: 24 5 2022
medline: 20 7 2022
entrez: 23 5 2022
Statut: ppublish

Résumé

Recent studies have suggested potential sex differences in treatment response to pharmacological therapies in heart failure (HF). We performed a systematic review and meta-analysis of studies comparing treatment effects between men and women with HF and reduced ejection fraction (HFrEF) using established guideline-directed medical therapy and other emerging pharmacological treatments. Systematic search was performed on PubMed, Embase, and Cochrane Library for randomized controlled trials published in 1990-2021. Outcomes were all-cause mortality and combined outcome of all-cause mortality and/or hospitalization for HF. Of 618 articles identified, 25 articles and 100 213 patients (mean age 62 ± 1.7 years, women 23.1%, mean left ventricular ejection fraction 26.6 ± 1.3%) were included in the systematic review and meta-analysis. For the outcome of all-cause mortality, there was no evidence of treatment heterogeneity by sex for renin-angiotensin system inhibitors (RASi) [hazard ratio (HR) 0.86 (95% confidence interval 0.75-0.99) in men; HR 0.97 (0.77-1.23) in women; P Our meta-analysis showed no differences between sex in treatment effect for BB and RASi. Review on previously published trials for MRA, SGLT2i, and emerging therapies presented consistent treatment effects between men and women.

Identifiants

pubmed: 35603531
doi: 10.1002/ehf2.13974
pmc: PMC9288771
doi:

Substances chimiques

Adrenergic beta-Antagonists 0
Angiotensin Receptor Antagonists 0
Angiotensin-Converting Enzyme Inhibitors 0
Mineralocorticoid Receptor Antagonists 0
Sodium-Glucose Transporter 2 Inhibitors 0

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2753-2761

Informations de copyright

© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
N Engl J Med. 2003 Apr 3;348(14):1309-21
pubmed: 12668699
N Engl J Med. 2020 Oct 8;383(15):1413-1424
pubmed: 32865377
Eur Heart J Cardiovasc Pharmacother. 2017 Jul 1;3(3):163-182
pubmed: 28329228
N Engl J Med. 1999 Sep 2;341(10):709-17
pubmed: 10471456
N Engl J Med. 2011 Jan 6;364(1):11-21
pubmed: 21073363
JAMA Intern Med. 2015 Jun;175(6):996-1004
pubmed: 25895156
J Am Coll Cardiol. 2021 Feb 16;77(6):772-810
pubmed: 33446410
BMJ. 2001 Jul 14;323(7304):101-5
pubmed: 11451790
Front Cardiovasc Med. 2021 May 07;8:630141
pubmed: 34026865
Am Fam Physician. 2009 Dec 1;80(11):1254-8
pubmed: 19961138
Eur Heart J. 2005 Aug;26(16):1585-95
pubmed: 15996977
Lancet. 2010 Sep 11;376(9744):875-85
pubmed: 20801500
N Engl J Med. 2021 Jan 14;384(2):105-116
pubmed: 33185990
Clin Pharmacokinet. 2009;48(3):143-57
pubmed: 19385708
Lancet. 2020 Sep 19;396(10254):819-829
pubmed: 32877652
J Am Heart Assoc. 2021 Feb;10(5):e018574
pubmed: 33619973
Curr Cardiol Rev. 2015;11(1):18-22
pubmed: 24251458
Heart Fail Clin. 2019 Jan;15(1):19-27
pubmed: 30449377
JAMA. 1995 May 10;273(18):1450-6
pubmed: 7654275
Eur J Heart Fail. 2020 May;22(5):834-844
pubmed: 32077220
Lancet. 2008 Sep 6;372(9641):807-16
pubmed: 18757088
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
N Engl J Med. 2020 May 14;382(20):1883-1893
pubmed: 32222134
ESC Heart Fail. 2022 Aug;9(4):2753-2761
pubmed: 35603531
N Engl J Med. 2019 Nov 21;381(21):1995-2008
pubmed: 31535829
Lancet. 2019 Oct 5;394(10205):1254-1263
pubmed: 31447116
N Engl J Med. 2014 Sep 11;371(11):993-1004
pubmed: 25176015

Auteurs

Cecilia Danielson (C)

National Heart Centre Singapore, 5 Hospital Drive, Level 10, Singapore, 169609, Singapore.
Department of Cardiology, Clinical Sciences, Lund University, Skåne University Hospital, Lund, SE-221 85, Sweden.

Gabriele Lileikyte (G)

National Heart Centre Singapore, 5 Hospital Drive, Level 10, Singapore, 169609, Singapore.
Department of Cardiology, Clinical Sciences, Lund University, Skåne University Hospital, Lund, SE-221 85, Sweden.

Wouter Ouwerkerk (W)

National Heart Centre Singapore, 5 Hospital Drive, Level 10, Singapore, 169609, Singapore.
Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam Infection & Immunity Institute, Amsterdam, The Netherlands.

Carolyn S P Lam (C)

National Heart Centre Singapore, 5 Hospital Drive, Level 10, Singapore, 169609, Singapore.
Duke-NUS Medical School, Singapore, Singapore.
Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

David Erlinge (D)

Department of Cardiology, Clinical Sciences, Lund University, Skåne University Hospital, Lund, SE-221 85, Sweden.

Tiew-Hwa Katherine Teng (TK)

National Heart Centre Singapore, 5 Hospital Drive, Level 10, Singapore, 169609, Singapore.
Duke-NUS Medical School, Singapore, Singapore.
School of Allied Health, University of Western Australia, Perth, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH